Please login to the form below

Not currently logged in
Email:
Password:

EGFR mutation

This page shows the latest EGFR mutation news and features for those working in and with pharma, biotech and healthcare.

Clock starts ticking on AZ’s first-line lung cancer filing in US

Clock starts ticking on AZ’s first-line lung cancer filing in US

Third-generation EGFR inhibitor Tagrisso (osimertinib) is already approved as a follow-up to older drugs in the class, including AZ’s own Iressa (gefitinib) product and Roche's Tarceva (erlotinib), ... were updated to include the use of Tagrisso in the

Latest news

  • AZ pushes harder into China with new joint venture AZ pushes harder into China with new joint venture

    The company made China a priority market for the roll-out of new lung cancer therapy Tagrisso (osimertinib), claiming approval for the EGFR inhibitor from the China Food and Drug Administration ... Asian patients with NSCLC have the EGFR mutation at

  • AZ starts pursuit of lung cancer indication for Imfinzi AZ starts pursuit of lung cancer indication for Imfinzi

    AZ starts pursuit of lung cancer indication for Imfinzi. And its EGFR inhibitor Tagrisso picks up US breakthrough status. ... The FDA awarded the status to the next-generation EGFR inhibitor for the first line treatment of patients with metastatic EGFR

  • AZ buoyed by latest lung cancer data at ESMO AZ buoyed by latest lung cancer data at ESMO

    to just over 10 months for first-generation EGFR-targeting drugs, Roche's Tarceva (erlotinib) and AZ's own Iressa (gefitinib). ... Until now, even with the therapeutic advances offered by the first- and second-generation EGFR inhibitors, less than 20% of

  • AZ gets rapid approval in China for Tagrisso AZ gets rapid approval in China for Tagrisso

    with NSCLC have the EGFR mutation at diagnosis. ... This is an important step forward for Tagrisso and a significant opportunity to bring a breakthrough medicine to patients with NSCLC in China, where EGFR mutation rates are some of the

  • Generic version of AZ’s Iressa launched in China Generic version of AZ’s Iressa launched in China

    Generics specialist Qilu is the first to launch a copycat version of AstraZeneca's EGFR inhibitor in China, with the firm losing patent protection for Iressa in the market in April ... The new generic, Yiruike, has been licensed by the Chinese regulatory

More from news
Approximately 1 fully matching, plus 52 partially matching documents found.

Latest Intelligence

  • Harnessing complexity Harnessing complexity

    While more established methodologies still dominate, Next Generation Sequencing is starting to make an impact in the Oncology CDx world, as this breakdown of methodologies used for EGFR mutation testing in

  • Transforming times at AstraZeneca Transforming times at AstraZeneca

    It is a particularly pressing matter for AZ considering the company has several personalised medicines on market or in development, including Iressa (gefitinib) to treat lung cancer patients with a mutation ... in the EGFR-TK gene and Lynparza, which is

  • Diagnostics are rising up the pharma value chain Diagnostics are rising up the pharma value chain

    lung cancer, which was backed together with Roche Diagnostics' cobas EGFR Mutation Test. ... He adds: “ What do we do when a person says they have a mutation of this type of cancer and there seems to be a drug.

  • Interview: AstraZeneca's Susan Galbraith Interview: AstraZeneca's Susan Galbraith

    If approved, the drug would complement AZ's other NSCLC drug, Iressa, which is approved in NSCLC patients with the EGFR mutation. “ ... Another development is AZD9291 – a drug which addresses the T790M mutation, which is a key resistance mechanism to

  • Interview: Allan Hillgrove, Boehringer Interview: Allan Hillgrove, Boehringer

    which received the green light as a treatment for patients with non-small cell lung cancer (NSCLC) who have the epidermal growth factor receptor (EGFR) gene mutation.

More from intelligence
Approximately 0 fully matching, plus 6 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
3 Monkeys Zeno

3 Monkeys Zeno is the UK arm of Zeno Group, a global integrated communications consultancy. Everything we do is rooted...

Latest intelligence

The threat of antimicrobial resistance
Why this issue is such a fundamental challenge...
Meet the CEO behind ReNeuron’s cutting-edge stem cell therapies
Blue Latitude Health speaks to Olav Hellebo, CEO of ReNeuron, to find out about the biotech’s latest innovation in stem cell therapy and to learn his perspective on navigating the...
Unique forum will unite NHS and industry to drive innovation
HSJ Life Sciences Forum will explore key NHS challenges and debate future of medicines, by Sarah Eglington, Client Services Director at Wilmington Healthcare...

Infographics